Abstract PS4-10-25: Intralesional Injection of IL-2 Prior to Surgery in Early-Stage Triple Negative Breast Cancer

Abstract BACKGROUND: Triple negative breast cancer (TNBC) represents 15-20% of all newly diagnosed breast cancers. This form of the disease, which tends to have a higher mutational burden, responds favorably to modern systemic immunotherapy. As a systemic treatment, immunotherapy is associated with rare but potentially life-threatening side-effects. For local, early-stage disease there may be an opportunity to employ targeted intralesional immunotherapy. Preliminary data suggests that intralesional injection of interleukin 2 (IL-2) may be able to produce a favorable pathologic response in TNBC. However, there are currently no protocols for the study of intralesional IL-2 in early-stage TNBC breast cancer. METHODS: This is a single-center, single-arm, non-randomized experimental trial with an initial target enrollment of 10 patients. Women 18-80 years of age with a